NICE, UK Rejects Gilead’s Yescarta for Being Too Expensive

 NICE, UK Rejects Gilead’s Yescarta for Being Too Expensive

NICE, UK Rejects Gilead’s Yescarta for Being Too Expensive

Shots:
  • NICE concludes that the ICER Yescarta vs salvage CT were above £50,000 per year making it expensive for use 
  • NICE also added considering ultra-orphan diseases that ICER for Yescarta was over £100,000 per QALY (Quality Adjusted Life)
  •  Consideration of making Yescarta available via Cancer Drug Funds has also been dropped by the committee. Consultation period for draft guidance runs until 18-Sep-2018
Click here to read full press release/ article | Ref: NICE| Image:  Forbes

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post